eli lilly lawsuit tirzepatide update sues Mochi Health and others for 'deceptive' marketing Eli Lilly weight loss drug

[Abstract]2025 Dec 10:S0891-5849(25)01425-X

Inflammatory Response to Weight Loss and Metabolic Changes Rapid fat breakdown can briefly raise inflammatory markers and release stored compounds from adipose tissue, which some people feel as muscle soreness or joint stiffness

According to the study, participants tolerated the treatment well

Administration of empagliflozin 25mg resulted in a higher proportion of patients achieving an HbA 1c goal of less than 7% and fewer patients needing glycaemic rescue than empagliflozin 10mg and placebo

This weight loss is primarily attributed to the drugs ability to decrease appetite and food intake, making it easier for patients to adhere to lower-calorie diets

This is what allows patients to lose weight